

****Published April 2022****

MarketVIEW: Epstein-Barr virus (EBV) vaccines (CAT: VAMV056)

Product Name	:	MarketVIEW: Epstein-Barr virus (EBV) vaccines
Description	:	Global vaccine commercial opportunity assessment
Contents	:	Executive presentation (>175 slides.pdf) + forecast model(s) (.xls)
Therapeutic Area	:	Epstein-Barr virus (EBV) vaccines
Publication date	:	April 2022
Catalogue No	:	VAMV056

Background

Epstein-barr virus (EBV) is a member of the herpesvirus family that exclusively infects humans, over 95% of adults worldwide harbor the virus. Primary EBV infections that occur in adolescence or early adulthood often result in infectious mononucleosis (IM), characterized by pharyngitis, cervical lymph node enlargement, fatigue and fever; complications can occur in around 1% of patients. Infectious mononucleosis is associated with an increased risk of Hodgkin lymphoma.

EBV is also associated with a variety of malignancies, including **gastric carcinoma**, **nasopharyngeal carcinoma**, **Hodgkin lymphoma** and **Burkitt lymphoma**. EBV is estimated to have caused ~1-2% of all global cancers in 2021 and is responsible for 140-200,000 deaths per year. EBV also causes Post transplant lymphoproliferative disorder (PTLD), a complication allogeneic hematologic stem cell transplants (HSCT) and to a less extent solid organ transplants (SOT). EBV is also involved with a heightened risk for multiple sclerosis [Bjornevik K et al 2022] and now possibly linked to long COVID-19.

This **MarketVIEW** product contains a comprehensive MS Excel-based model + Executive presentation that forecasts the potential commercial value of Epstein-barr virus (EBV) vaccines across Western economies¹ until 2040. The model contains value (\$ m) and volume (mio doses) predictions per identified vaccine target segment along with timeframe, pricing and penetration estimates for three **target product profiles (TPPs)** including prophylatic [PX] and therapeutic approaches [TX]. The product also includes an in depth review of latest EBV epidemiological trends, treatments/guidelines, comparative pricing assessments and latest developments in vaccinology and R&D including Moderna Therapeutics **mRNA-1189**, prophylatic vaccine and **mRNA-1195**, therapeutic vaccine, the former of which has now entered Phase I clinical development.

¹ US, Canada, UK, France, Germany, Italy, Spain, Other Europe, Australia, Japan, South Korea

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to Epstein-Barr virus (EBV) vaccines in each respective market. Source materials used are academic literature articles, government websites, medical bodies and associations, conference proceedings, social media etc. Previously published research by **VacZine Analytics** in the field of viral pathogens has also been utilised.

PRODUCT CONTENTS:

Published January 2022 (CAT No: VAMV056)

****This product is a [summary presentation \(.pdf\)](#), [an MS-workbook \(.xls\)](#)

Contents – Summary presentation (.pdf)



Contents

Author's notes

Executive summary

Commercial model: key outputs

[SECTION 1] Epstein-Barr virus: background to the virus

[SECTION 2] Epstein-Barr virus: related disease manifestations

[SECTION 3] Epstein-Barr virus: summary of vaccine development, current R&D

[SECTION 4] Epstein-Barr virus vaccines: Modelling commercial potential

- *Prophylactic (PX) approaches*
- *Therapeutic (TX) approaches*

[SECTION 5] Epstein-Barr virus vaccines forecast: Methodology

References/bibliography

About **VacZine Analytics**

Disclaimer

SNAPSHOT

PAGES: >175 slides fully referenced/sourced. Available in .pdf form

Contents – MS-Excel workbook (.xls)



United States [5 target populations, 4 Target Product Profiles, TPPs]

Canada

UK

France

Germany

Italy

Spain

Other Europe*

China

Australia

Japan

South Korea



PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD **\$12,995.00**/ GBP **£10,500.00**# (Region license)*

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20% will be added to final invoice total

- indicative prevailing rate will be applied on date of transaction

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics © is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics © and the “spiral logo” are UK Registered Trademarks, 2009

BIBLIOGRAPHY

References – available upon request



TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. All Rights Reserved. This finished research product is a licensed product. It may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the Company **VacZine Analytics** (of division of Assay Advantage Ltd).
2. The license granted by the Company to the Client will be non-exclusive, non-transferable and should only be used for the Client business purposes at the agreed Client sites/location in accordance with this agreement. The Client will have no ownership rights over the research product.
3. Invoicing will **100%** after submission of the deliverables (.pdf) and (.xls) to the Client.
4. If not purchased on line invoices are payable within **thirty days** of the invoice date.
5. All proposals are quoted in **\$USD dollars or £GBP or €euro** and invoices are to be settled in the same currency.
6. The Company agrees not to disclose to any third-party confidential information acquired in the course of providing the research product listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
7. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster including pandemic, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
8. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

A division of Assay Advantage Ltd
Warren (Carlton) House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 927049
E-mail: info@vaczine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics ® is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics ® and "the spiral logo" are UK Registered Trademarks, 2009



Since 2007

